Opens in a new tab

Breaking news

How Americans Can Conquer Retirement Anxiety Without Running Out Of Resources

Facing the Retirement Financial Challenge

Recent studies reveal a growing concern among Americans: the fear of outliving their retirement savings has taken precedence over other anxieties. According to a survey by Allianz Life, 64% of Americans fear running out of money more than they fear death. Interestingly, this fear spans across generations, including Gen Xers, millennials, and baby boomers.

This concern stems from several factors such as inflation, insufficient Social Security benefits, and overwhelming tax obligations. This fear is not unfounded, considering new tariff policies impacting the stock market and inflation predictions.

A New Perspective on Retirement Strategy

Managing the worry of exhausting retirement funds involves reassessing how retirement is funded. With the decline of pensions, reliance shifts to 401(k) plans and personal investments. Professionals like David Blanchett from PGIM DC Solutions suggest creating a guaranteed lifetime income stream through delaying Social Security benefits and purchasing annuities.

While annuities require a significant up-front sum, they offer a dependable income stream. Yet, hesitation remains due to the complexities involved and a lack of widespread adoption.

Boosting Confidence Through Strategic Planning

Experts emphasize the importance of consulting with financial advisors. Kelly LaVigne of Allianz Life advocates for personalized planning, reflecting on factors like market returns and inflation. Comprehensive financial planning can bridge the confidence gap that many retirees face.

Ultimately, retirement is a personal journey influenced by numerous variables. A thoughtful and informed approach can alleviate the fear and help ensure a financially secure future.

Cyprus Joins European Genome Project To Advance Personalised Medicine

Genetic information could help doctors identify which treatments are most likely to work for individual patients, predict potential side effects and uncover inherited causes of diseases that are difficult to diagnose. Cyprus is contributing to a major European initiative aimed at making this approach more effective by expanding the understanding of genetic diversity across the continent.

The Genome of Europe programme brings together 49 partners from 27 countries to establish a shared reference database containing at least 100,000 human genomes. With a budget of €45 million, including €20 million from the European Commission’s Digital Europe programme, the initiative began in autumn 2024 and is scheduled to run for three and a half years.

Cyprus is participating through biobank.cy, the Centre of Excellence for Biobanking and Biomedical Research at the University of Cyprus. Its contribution includes sequencing the complete genomes of at least 310 Cypriot volunteers.

Why Europe Needs A More Diverse Genetic Reference

Although most human DNA is shared, small genetic differences can influence inherited conditions, disease susceptibility and how individuals respond to medicines.

These variations differ between populations. A reference database based primarily on a limited range of genetic backgrounds may therefore provide less accurate insights for groups that are underrepresented. Genome of Europe aims to address this gap by building a dataset that better reflects the continent’s genetic diversity.

“Populations, such as that of Cyprus, have their own specific characteristics,” said Katerina Strati, an associate professor in the University of Cyprus’s Department of Biological Sciences. She explained that findings from other populations cannot automatically be applied to Cypriots.

A population-specific reference genome gives researchers a baseline against which to assess genetic variants, helping them determine whether a particular variation is common or rare among people with a similar background. This can improve the interpretation of genetic tests and research into disease risks.

Mapping The Genetic Profile Of Cyprus

Efforts to map the genetic profile of the Cypriot population began in 2019. Through the Cypriot Human Genome Project, known as CYPROME, researchers have already analysed more than 1,000 exomes from local volunteers. Unlike whole-genome sequencing, which examines a much broader portion of DNA, exome sequencing focuses on the protein-coding regions of genes.

Apostolos Malatras, a senior bioinformatician at biobank.cy, said population-specific genetic data could help researchers interpret individual findings more accurately and eventually support better-informed treatment decisions.

The centre’s research infrastructure includes more than 123,000 biological samples, 12,257 volunteers and participation in 14 research programmes. These figures represent different measures: one volunteer may provide multiple samples, and sample collection does not necessarily mean that a genome has been sequenced.

Its research covers hereditary kidney diseases, heart conditions and other illnesses, including work on preclinical models for rare kidney diseases such as Alport syndrome.

Malatras said a better understanding of genetic differences could eventually help develop more personalised medicines and improve treatment selection.

Mariel Voutounou, a project manager at the centre, compared the development of new treatments to a long-distance race. Building the necessary collection of biological samples and research data takes time, she said, but an established biobank gives scientists a valuable starting point.

Protecting Genetic Data And Volunteer Rights

Because genetic information can reveal details about a person’s health and potentially affect their biological relatives, data protection and informed consent are central to the project.

biobank.cy operates with approval from the National Bioethics Committee of Cyprus and complies with the EU’s General Data Protection Regulation. Its safeguards include technical and organisational measures to restrict access to personal information.

Georgia Charalambidou, who leads the centre’s work on ethical, legal and social issues and education, said volunteers receive information about the research, have time to consider participation and can ask questions before signing a consent form.

Participation is voluntary, and individuals can withdraw their consent at any time without affecting their medical treatment or relationship with their doctor.

The centre has also surveyed approximately 569 people in Cyprus to understand public attitudes towards genetic testing and research participation. According to Charalambidou, the findings indicated broad support for genetic research, alongside clear expectations about transparency and how personal data are used.

The results also suggested that people with experience of patients diagnosed with a particular condition were more likely to favour receiving genetic findings through specialist doctors. This highlights the importance of explaining both the potential benefits and the limitations of genetic testing.

Sharing Research Without Transferring Sensitive Data

International cooperation presents another challenge: enabling researchers to compare genetic information across countries while protecting sensitive personal data.

The European Genomic Data Infrastructure is designed to connect national systems securely. Rather than transferring underlying files between countries, researchers can conduct analyses within the systems where the data are stored, Malatras explained.

This approach is particularly relevant to rare diseases, where individual countries may have relatively few diagnosed cases. Comparing data across populations can help researchers identify genetic patterns that might otherwise remain difficult to detect.

From Genetic Research To More Personalised Treatment

Precision medicine is already used in some areas of healthcare, particularly oncology, where genetic information can help guide treatment decisions. However, developing medicines tailored to each patient’s genetic profile remains a longer-term ambition.

Genome of Europe aims to strengthen the evidence base needed to advance this approach. Its success will depend not only on the number of genomes collected but also on how accurately researchers interpret the data, represent different populations and translate findings into safe clinical applications.

For Cyprus, contributing genetic data from its population will help ensure that local genetic characteristics are represented in European research. In the longer term, this could support earlier diagnoses, more informed prevention strategies and treatments better suited to individual patients.

Uol
Aretilaw firm
The Future Forbes Realty Global Properties
eCredo

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter